Treatment of Lupus Tumidus with Severe or Disseminated Skin Lesions When First-Line Antimalarial Combination Therapy Did Not Work

This protocol covers the management of lupus tumidus presenting with severe or disseminated cutaneous lupus erythematosus (CLE) skin lesions in patients where the initial treatment line failed to achieve the expected response.

Clinical Scenario

Severe or disseminated cutaneous lupus erythematosus skin lesions. Antimalarial drugs are the recommended first-line approach — including for long-term therapy — in all CLE patients with severe and disseminated skin lesions, particularly when there is a risk of scarring.

First-Line Failure — Escalation Trigger

The preceding regimen — mepacrine in combination with hydroxychloroquine or chloroquine — did not produce the expected improvement of skin lesions within 3–4 weeks (maximum effects anticipated at 6–8 weeks). Failure to meet these response targets is the clinical trigger for advancing to this next-line protocol.

Next-Line Approach — Partial Overview

For this situation, a systemic disease-modifying agent administered on a weekly schedule is indicated, preferably alongside continued antimalarial therapy. The treatment goal is improvement of cutaneous lupus erythematosus disease activity, with efficacy evaluated after 3–6 months of treatment.

The specific agent, route of administration, co-medication details, and monitoring guidance are covered in full in the structured protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ddg.14491

Antimalarial drugs are recommended as first-line treatments, also for long-term therapy, in all CLE patients with severe and disseminated skin lesions; in particular for patients with a risk of scarring.

For severe or disseminated CLE lesions, systemic glucocorticoids are recommended as first-line treatment in addition to antimalarial drugs, for a limited period of time.

MTX is recommended as a systemic second-line treatment at doses of up to 25 mg per week, and if possible in combination with antimalarial drugs.

During MTX treatment, a single oral dose of 5 mg folic acid should be given on the next day to reduce possible side effects.

Weekly doses of 15 mg and above are usually tolerated better if applied subcutaneously.

It is recommended to evaluate the efficacy of systemic treatment for CLE after a minimum of three months and a maximum of six months (except for glucocorticoids).

View source ↗